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Summary 
Introduction: Opicapone is a third generation, highly potent and effective catechol 
O‑methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L-
DOPA therapy. 
Areas covered: In this review, we describe the preclinical and clinical development of opicapone. In 
PD patients with motor fluctuations, once daily opicapone administration was well-tolerated and 
consistently reduced OFF-time and increased ON-time without increasing the frequency of 
troublesome dyskinesia, and these benefits were maintained over at least a year of continued open-
label therapy.  
Expert commentary: With its convenient once-daily regimen, adjunct opicapone should be 
considered as an effective option for use in L-DOPA treated PD patients experiencing motor 
fluctuations. 
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1. Introduction  
Parkinson’s disease (PD) has a prevalence of 1 in 800 people, with advancing age being by far the 
greatest risk factor. It is predicted that the PD patient population will at least double by 2030 [1], 
and the associated increase in medical costs will be considerable [2]. Although the choice of initial 
therapy  depends on age of onset  of symptoms, disease severity, co-morbidities and patient 
preference, L-DOPA  remains the most  efficacious and widely used symptomatic treatment for PD 
[3] and almost  all patients will eventually receive the drug at some stage during their illness [4]. 
 
The first few years of L-DOPA therapy are often referred to as the ‘honeymoon phase’ [5], but with  
longer disease duration and greater cumulative exposure to L-DOPA [6], most patients eventually 
experience L-DOPA–induced complications, including response fluctuations and dyskinesia. For 
many patients, the first sign of these is when they begin to notice a decline in the duration of 
therapeutic benefit  from each L-DOPA dose, a phenomenon commonly termed ‘wearing-off’, which 
is defined as “a generally predictable recurrence of motor or non-motor symptoms that precedes a 
scheduled dose and usually improves after the administration of antiparkinsonian medication” [7]. A 
considerable literature exists on the possible pathophysiology and management  of wearing-off 
fluctuations   [7-12]. Up to 50% of patients can develop mild motor fluctuations within 2 years of 
initiating L-DOPA therapy [5, 6], with the ELLDOPA study reporting wearing-off within 5 to 6 months 
in some patients [7]. Up to 70% of patients receiving L-DOPA will have response fluctuations after 9 
years of  sustained treatment [13]. 
 
Response fluctuations  lead to a deterioration of quality of life [14, 15], a recent survey of over 3000 
PD patients found that over 90% of patients experience at least one OFF episode per day and 65%   
spend at least two hours per day in the OFF state [16]. 
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2. L-DOPA related response fluctuations: overview of current treatment options  
2.1 L-DOPA adjustments 
Fragmentation of total daily L-DOPA intake into smaller and more frequent doses should 
theoretically provide more consistent plasma levodopa levels, and thus more consistent symptom 
control. However, the use of lower frequent doses can lead to  dose failures and even more 
unpredictable motor responses in some cases  [7]. Physicians may also consider increasing individual 
L-DOPA dose(s) at the times of the day when the patient finds wearing-off to be most troublesome, 
but while sometimes effective, this approach may increase the risk of dyskinesias [17]. Dietary 
protein restriction, treatment of constipation and dosing at least one hour before meals may all also 
be helpful in selected patients. 
 
2.2 Adjunct therapies 
Current national and international treatment guidelines all consider dopamine agonists,  
monoamine oxidase type B (MAO-B) inhibitors and catechol O‑methyltransferase (COMT) Inhibitors, 
as efficacious for adjunct use with L-DOPA to reduce motor fluctuations [18, 19]. Although effective 
in the management of response fluctuations, the recognition of significant risks of developing 
impulse control disorders (ICDs) and other adverse effects [20] has led to a decline in the early use of 
dopamine agonists such as  ropinirole and pramipexole [21].  MAO-B inhibitors, such as selegiline 
and rasagiline are effective in the treatment of mild end of dose deterioration [22], although there is 
less evidence for selegiline in this indication [19]. Recently, a ‘third generation’ MAO-B inhibitor 
safinamide has also received EU market approval as an adjunct to L-DOPA for PD patients 
experiencing response fluctuations [23].   
 
The COMT inhibitor entacapone is a common first-line strategy for the management of wearing-off, 
but like the MAO-B inhibitors, reductions in daily OFF-time are moderate (mean of 41 minutes 
across clinical trials) and it has to be given with each L-DOPA dose [24]. Tolcapone is a more 
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efficacious COMT inhibitor than entacapone [24], but its practical utility is restricted by the potential  
risk of liver toxicity necessitating regular monitoring of liver function and  is only indicated for 
patients who failed to respond to  entacapone [19, 25]. There is therefore a need for a more 
effective COMT inhibitor that can be easily used in routine clinical practice [26]. 
 
2.3 New L-DOPA formulations 
Until recently, the available controlled release L-DOPA formulations such as Madopar CR and 
Sinemet CR have proved disappointing in the management of motor fluctuations and are now mainly 
used for the management of nighttime-akinesia. The last few years has seen considerable interest in 
the development of more efficacious L-DOPA formulations that address its pharmacokinetic 
limitations. The first of these new formulations to receive regulatory approval is IPX066 
(Rytary/Numient) which is described as an extended-release L-DOPA capsule containing combined 
immediate- and sustained-release pellets of L-DOPA/carbidopa. IPX066 has been shown to provide a 
greater reduction of OFF time and a greater increase in ON time without troublesome dyskinesia 
when compared to standard immediate release (IR) L-DOPA therapy and the combined L-
DOPA/carbidopa/entacapone (Stalevo) formulation [27, 28]. It remains to be seen whether these 
promising trial results will be borne out in clinical practice and it is currently unclear if this drug will 
be reimbursed in the EU at a level that would make its introduction into the market attractive from 
the business perspective. 
 
Other L-DOPA formulations including a gastric-retentive (accordion pill) formulation [29], a sustained 
release formulation of a L-DOPA prodrug [30], a formulation for subcutaneous delivery [31] and an 
intrapulmonal delivery system [32] have reached clinical development.  
 
3. Introduction to opicapone  
Opicapone (Ongentys, manufactured and marketed by BIAL‑Portela & Cª, S.A. Portugal) received 
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approval for Marketing Authorization from the European Commission in June 2016 as adjunctive 
therapy to preparations of L-DOPA/DOPA decarboxylase inhibitors (DDCIs) in adult patients with PD 
and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Based on 
research into the structure and function of the COMT enzyme and using an analogue-based research 
approach, opicapone was designed and developed in-house by BIAL to reduce the risk of toxicity and 
improve tissue selectivity compared with other COMT inhibitors [33]. 
 
3.1 Chemistry  
Opicapone (2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-
dimethylpyridine 1-oxide (previously known as BIA 9-1067) is a hydrophilic 1,2,4-oxadiazole 
analogue with a pyridine N-oxide residue at position 3 to provide high inhibitory potency and avoid 
cell toxicity (Figure 1) [34].  
 
[Figure 1 near here] 
 
Opicapone has been designed as a ‘tight-binding’, reversible COMT inhibitor which means it is a 
highly selective inhibitor of COMT versus the other enzymes involved in catecholamine metabolism. 
It has a high binding affinity (sub-picomolar Kd) resulting in a long residence time of the reversible 
COMT–opicapone complex, and translating into a slow complex dissociation rate constant, suitable 
for once-daily administration [34, 35].  
 
3.2 Pharmacodynamics  
In vivo, the duration of COMT inhibition by opicapone, extends far beyond the observable point of 
clearance of circulating drug, and reflects an underlying kinetic process that is consistent with the 
slow dissociation rate constant of the COMT-OPC complex [36]. In a time course experiment 
conducted in rats opicapone achieved the maximum inhibitory (99%) effect on COMT within 3 hours 
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of oral administration, which was continued by 80−90% inhibition for up to 9 hours and a gradual 
return to lower levels over the next 15 hours [33]. In liver and brain homogenates of rats given L-
DOPA/benserazide and equivalent doses of COMT inhibitors via gastric tubes; opicapone 
demonstrated a stronger and more sustained COMT inhibitory effect than both entacapone and 
tolcapone. At 1-hour post-administration COMT inhibition was 99% with opicapone versus 82% with 
tolcapone and 68% with entacapone. At 9 hours post-administration the level of COMT inhibition 
remained at high levels (91%) with opicapone, but tolcapone only had residual effects (16% 
inhibition) and the COMT inhibitory effects of entacapone had worn off [37].  
 
Opicapone does not cross the blood-brain barrier of rats [34] or monkeys [37]. Chronic 
administration of opicapone to cynomolgus monkeys doubled the bioavailability of systemic L-DOPA, 
by shifting Tmax later and without affecting Cmax values, and reduced both 3-O-methyldopa (3-
OMD) exposure and Cmax values by 5-fold. These changes were accompanied by 76–84% reduction 
in erythrocyte COMT activity. Microdialysis revealed that opicapone increased L-DOPA exposure in 
the dorsal striatum by 170%, the substantia nigra by 140% and in the prefrontal cortex by 230% – all 
with concomitant reductions in 3-OMD exposure [37]. 
 
3.3 Pharmacokinetics and metabolism  
3.3.1 Opicapone pharmacokinetics 
In healthy volunteers, pharmacokinetic dose-proportionality in terms of Cmax and AUC0-∞. has 
observed for opicapone (10-1200 mg) and its metabolites; the apparent terminal elimination half-life 
of opicapone was 0.8–3.2 hours [36].  
 
The major metabolic pathway of opicapone is sulphation (resulting in the inactive metabolite BIA 9-
1103) with other metabolic pathways including reduction, methylation, and glucuronidation. By 
contrast, the metabolite formed by reduction of the pyridine-N-oxide to pyridine ring (BIA 9-1079) is 
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active, but accounts for less than 15% of systemic exposure to opicapone and its contribution to the 
overall clinical effect is assumed to be of minor clinical relevance. Since urine levels of opicapone 
and its major metabolites remained below the limit of quantification in the opicapone dose range 
tested (10 to 1200 mg), it is thought that the biliary route is likely to be the main route of opicapone 
[36]. This is supported by a mass balance recovery study conducted in 6 healthy male volunteers, 
where the major route of excretion of [14C]-radioactivity was via feces (arithmetic mean = 67.2%). 
The remainder of [14C]-radioactivity was excreted in urine and via expired air (arithmetic mean = 
12.8% and 15.9%, respectively).  In this study, single doses of [14C]-opicapone 100mg were rapidly 
absorbed; the median tmax for opicapone in plasma was 2.51 hours [38]. 
 
A high fat meal decreased the rate and extent of absorption of opicapone, with delayed peak plasma 
levels as compared to drug administration under fasting conditions [36].  It is recommended, 
therefore, that opicapone should not be taken with food – and a minimum interval of one hour can 
be recommended. 
 
3.3.2 Effect on COMT and L-DOPA pharmacokinetics 
In the tested dose range (10-1200 mg), single doses of opicapone had a dose-dependent inhibitory 
effect on erythrocyte soluble COMT activity with a maximum S-COMT inhibition (Emax) ranging from 
34.5% (with the 10 mg dose) to 100% (with doses >200mg), and an inhibition of 25.1 to 76.5% 
remained at 24-hours post-dosing [36]. This effect was independent of the dose taken, and the half-
life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 hours [36]. This long 
lasting effect is thought to reflect the slow dissociation of the tightly bound COMT-opicapone 
complex, and was replicated in repeat dose studies where the extent of S-COMT inhibition was 
shown to be significantly longer with opicapone (25-75mg doses) versus entacapone [39].   
 
Age, gender, ethnicity (Caucasian versus Japanese), and COMT polymorphism have not been found 
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to exert relevant effects on the pharmacokinetics or pharmacodynamics (S-COMT inhibition) of 
opicapone that would warrant a dose adjustment in any patient subgroup [40]. Although opicapone 
exposure was increased in subjects with moderate hepatic impairment (Child-Pugh B) relative to 
matched healthy subjects, due to its short half-life and complete clearance from systemic circulation 
before the subsequent dose, no dose adjustment for opicapone needs to be considered [41]. 
Although there are no data in patients with renal impairment, since opicapone is not excreted by the 
kidney no dose adjustments are needed in patients with renal impairment [40].  
 
[Figure 2 near here] 
 
In healthy volunteers, once daily administration of opicapone (25–75mg) dose-dependently 
increased the minimum (trough) plasma concentrations (Cmin) of repeat doses of L-DOPA compared 
to placebo [39]. The 50mg opicapone dose increased L-DOPA trough levels by 260% (versus placebo) 
compared with a 190% increase with entacapone [39]. Peak L-DOPA values (Cmax) increased by 110 
– 130% versus placebo at the second and third L-DOPA administrations with opicapone 50mg. 
Although L-DOPA peak levels were similar or even slightly lower with concomitant administration of 
entacapone 200mg, there was no statistical difference for L-DOPA Cmax between the active 
treatments (opicapone and entacapone) and placebo [39]. In accordance with these changes, 
administration of 50 mg opicapone was associated with a statistically significant increase in the 
bioavailability of L-DOPA (as assessed by concentration-time curve (AUC)) versus placebo. By 
contrast, no statistical difference was found for L-DOPA AUC when entacapone was compared to 
placebo [39]. 
 
In PD patients experiencing motor fluctuations, administration of opicapone has been consistently 
shown to dose dependently increase L-DOPA bioavailability versus placebo [42, 43]. In one study, L-
DOPA bioavailability increased by 16.4% with a single dose of opicapone 50mg and 34.8% with a 
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single dose of opicapone 100 mg [43]. Repeat dosing (over 28 days of maintenance dosing) showed a 
higher magnitude of effect of up to 65.6%, but the highest opicapone dose tested in this study was 
30 mg [42].   
  
3.4 Clinical efficacy  
3.4.1. Phase II studies  
The Phase II clinical program focused on the effects of single and repeat dosing of opicapone on L-
DOPA pharmacokinetics, including two clinical studies which evaluated the efficacy of opicapone in 
reducing OFF time and increasing ON time as exploratory outcomes [42, 43]. 
 
In a study of single opicapone doses, administration of opicapone 50 mg increased ON time by 25% 
compared with placebo. For this dose, ON time without dyskinesia increased by 73% versus placebo. 
Conversely, ON time with dyskinesia decreased by 34% [43]. This benefit was also observed in a 
study of repeat opicapone doses (once daily for 28 days), which showed a similar dose-dependent 
change in absolute OFF time (as assessed by patient diaries) corresponding to a percentage decrease 
of 4.16% (15.6 minutes, p>0.05), 29.55% (116.9 minutes, p>0.05) and 32.71% (145.0 minutes, 
p<0.05) with 5, 15 and 30 mg opicapone, respectively [42]. The percentage of OFF time reduction 
was similar to the percentage increase of ON time without dyskinesia, with both 15 and 30 mg 
opicapone reaching a statistical difference to placebo for the ON time without dyskinesia (P = 0.0162 
and P = 0.0065, respectively) [42]. In this study, administration of opicapone was also reported to 
decrease the time to ON (interval between time of ON start after L-DOPA test dose and time of L-
DOPA test dose intake), time to best-ON (interval between time of best-ON start after L-DOPA test 
dose and time of L-DOPA test dose intake) [42].  
 
3.4.2 Phase III studies  
The Phase III  program was based on two large scale, multicenter, double-blind trials with their 1 
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year open label extensions [44, 45] in 1,027 randomized adult patients with PD treated with L-
DOPA/DDCI (alone or in combination with other antiparkinsonian drugs) and end-of-dose motor 
fluctuations. 
 
The first study, BIPARK I – was a randomized, double-blind, placebo-controlled and active-controlled 
trial of three doses of opicapone (5 mg, 25 mg, and 50 mg once daily) as an adjunct to L-DOPA in PD 
patients with end-of-dose motor fluctuations [44]. The active control was entacapone (200 mg with 
every L-DOPA intake), and the primary endpoint was the change from baseline to study-end in 
absolute OFF time. According to the hierarchical analysis, the opicapone 50 mg group had the most 
consistent efficacy and met the primary efficacy outcome of superiority compared with placebo and 
non-inferiority compared with entacapone in reducing OFF time [44]. The mean reduction of 60.8 
minutes in OFF time versus placebo (p=0.0015) has previously been established as clinically  
meaningful [46, 47], and the reductions in OFF time were accompanied by a corresponding increase 
in time in ON time without troublesome dyskinesia (62.6 minutes; p=0.002). Importantly, the 
duration of ON time with troublesome dyskinesia did not change [44].  
 
The inclusion of entacapone as an active control not only validated the findings of the trial (by 
showing expected efficacy of entacapone in this population of patients), but also helps understand 
the potential differences between opicapone and entacapone. Assessments of global health status 
using the Clinician´s Global Impression of Change (CGI-C) and the Patient’s Global Impression of 
Change (PGI-C) indicated clinically significant improvements for opicapone 50 mg versus both 
placebo (CGI-C, p=0.0005; PGI-C, p=0.0070) and entacapone (CGI-C, p=0.0008; PGI-C, p=0.0091), 
reflecting a better functioning or well-being of the patients versus entacapone (Figure 3). Likewise, 
responder rates for reductions in OFF time (patients with a reduction of ≥ 1 h in OFF time; 70% of 
patients) and increases in ON time (patients with an increase of ≥ 1 h in ON time; ≤ 65% of patients) 
were significantly higher for the opicapone 50 mg dose (OFF time, p=0.003; ON time, p=0.0001) than 
 13 
for placebo, which was not the case for entacapone [44]. 
[Figure 3 near here] 
 
The second study, BIPARK II – was also conducted as a multicenter, randomized, double-blind 
placebo-controlled study, without an active comparator [45]. As in the earlier study, opicapone 
50mg significantly reduced OFF time by an average of 54 minutes versus placebo (p=0.0084), and 
this was accompanied by corresponding improvements in absolute ON time. Once again, most of the 
gain of ON-time with opicapone was without troublesome dyskinesia and increases in ON-time with 
troublesome dyskinesia were not significantly different from placebo for both groups. Significantly 
more patients receiving 50 mg opicapone achieved the OFF time responder endpoint (patients with 
a reduction of ≥ 1 h in OFF time; 62.4%, p=0.0405). 
 
In this study, change from baseline in Unified Parkinson’s Disease Rating Scales (UPDRS) Part III 
(motor) scores was included as the third secondary measure to be assessed in a hierarchical 
procedure. UPDRS motor scores were not improved versus placebo, and so it should be noted that 
the improvements in ON time as described above should be considered exploratory. Indeed, in both 
pivotal studies, changes in UPDRS motor function were small and similar across all groups [44]. It is 
thought this is probably because the patients were already receiving L-DOPA treatment for 
symptomatic control, and such small changes have been a feature of most previous COMT inhibitor 
trials [48].  
 
The results of these two studies were reassuringly consistent, with the 50 mg dose providing the 
most consistent efficacy although therapeutic benefits with the 25 mg dose were also apparent in 
some patients. The similarity of trial design between the two large studies (similar designs, identical 
eligibility criteria and consistent assessment methods) permits a pooled analysis of OFF and ON time 
changes across the two studies [49]. When analyzed in this way, treatment both opicapone 25mg 
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(n=241) and 50mg (n=262) significantly reduced daily OFF-time (-37.4 min and -64.4 min vs. placebo 
(n=255); p<0.05 and p<0.0001, respectively) and increased the ON-time without troublesome 
dyskinesia (42.7 min and 64.7 min vs. placebo; p<0.05 and p<0.0001, respectively) (Figure 4) [49]. No 
significant differences were observed for the ON-time with troublesome dyskinesia.  
 
[Figure 4 near here] 
 
Results of the open-label phases of the pivotal trial indicate a maintenance of effect [50]. In both 
studies, OFF-time reductions from double-blind baseline were sustained (or even further improved) 
over the open-label phases and, as expected, these reductions were accompanied by increases in 
ON time (BIPARK II, Figure 3). Findings from the BIPARK II open-label extension appear to indicate a 
benefit of earlier initiation; results at the end of the open-label phase were numerically better for 
the patients in the original opicapone groups versus those who were originally assigned to placebo 
[45]. In the BIPARK I open-label extension, patients who switched from entacapone treatment in the 
double-blind phase to open-label treatment with opicapone experienced a further statistically 
significant reduction in OFF time of -39.3 minutes (p<0.05) with a corresponding increase of ON-time 
without dyskinesia of 46 minutes (p=0.0148). By the end of the one year open-label phase, the 
means for OFF time were similar, irrespective of original double-blind allocation [50] (Figure 5) [51]. 
 
[Figure 5 near here] 
 
Further support for the benefits of long-term opicapone treatment comes from ratings of global 
function as perceived by patients and investigators. In both studies, improvements in global function 
at the end of the double-blind period were maintained after 1 year of treatment in the open-label 
extensions. Across the studies, about 60% of the subjects at the end of the open-label period were 
assessed by investigators and subjects as having improved (i.e. minimally, much or very much 
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improved) relative to the double-blind baseline, which was slightly above the rate observed at the 
end of the double-blind periods [38]. 
 
L-DOPA dosing is often used as a proxy of efficacy, and in a progressive disease maintenance of 
dosing and dosing frequency can be said to reflect sustained control of motor fluctuations over the 
long term. It is therefore of note that, in the BIPARK II study, almost two-thirds (63%) of patients 
were maintained on the same dose of L-DOPA, despite freedom adjust dosing according to clinical 
need [45]. The average number of daily L-DOPA intakes also remained stable during this phase, 
ranging from 4.69 to 4.76 over the course of the year. 
 
[Figure 6 near here] 
 
3.5 Safety and tolerability 
During the clinical development program, opicapone was administered (single or multiple doses) to 
a total of 1651 subjects: 859 healthy subjects and 792 subjects with PD [40]. In all studies, opicapone 
has been generally well tolerated with no apparent dose-relationship for the majority of treatment-
emergent adverse events (TEAEs). 
 
Studies in healthy volunteers have confirmed that the 50 mg dose of opicapone is not associated 
with a clinically significant effect on cardiac repolarization as measured by the QTc intervals [52] 
with no clinically significant out-of-range value in hematology, blood chemistry or urinalysis 
parameters, no clinically significant out-of-range value in vital signs or ECG parameters [38]. Other 
Phase I studies show that although co-administration of paracetamol causes a significant decrease in 
opicapone sulphation and therefore reduced levels of the BIA 9-1103 metabolite, it has no effect on 
opicapone exposure or tolerability profile in healthy volunteers [40]. 
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This favorable tolerability profile in healthy volunteers has also been consistent in the Phase II and III 
studies conducted in patients with PD and motor fluctuations. Overall, the incidence of TEAEs and 
related TEAEs has been higher with opicapone than with placebo in the double-blind phases (Table 
1) [53]. Across both studies, the percentage of patients who discontinued because of TEAEs was low 
and similar across the treatment groups. Few patients discontinued opicapone therapy due to TEAEs 
and the high retention of patients across the double-blind and open-label extension phases support 
the good tolerability of repeated treatment [45, 53].  
 
Across both double-blind studies, the most common TEAEs reported in the opicapone group 
compared to placebo were the dopaminergic events of dyskinesia, constipation, insomnia, dry 
mouth and dizziness, as well as increased blood creatine phosphokinase (CPK). L-DOPA is frequently 
the drug of choice for older patients [4], and in this respect it is noteworthy that opicapone appears 
to be equally well tolerated in older PD patients over the age of 70 years (also with equivalent 
efficacy) [54]. When analyzed by age (<70 versus >70 years old), TEAEs occurring more frequently in 
older versus younger patients included constipation (8.5% vs 4.5%); dizziness (7.2% vs 2.2%), visual 
hallucinations (5.2% vs. 0.6%), nausea (5.2% vs. 3.1% and weight decreased (4.6% vs. 1.1%) [54]. 
During open-label treatment the incidence of most of these TEAEs remained similar to the double-
blind phases. In the extension of BIPARK II, there was an increased incidence of falls and depression, 
which is likely a reflection of the natural progression of the underlying disease and associated co-
morbidities. In particular, increased blood CPK went from 4.9% of subjects in the opicapone 50 mg 
group to 7.4% of all subjects in the OL extension. As increased CPK levels are often associated with 
muscular lesions due to falls or accidents, dyskinesia, and PD in general, this increased incidence 
probably also reflects the natural incidence of associated co-morbidities of the underlying disease 
over a longer period of observation.  
 
[Table 1 near here] 
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Dyskinesia was the most frequently reported TEAE considered related to the study drug, with a 
higher incidence in the combined opicapone groups (17.7%) than either placebo (6.2%) or 
entacapone (7.4%) groups. The higher level of dyskinesia with opicapone versus entacapone is in line 
with opicapone’s more potent inhibition of COMT resulting in greater L-DOPA bioavailability. For 
reasons of data interpretation, both Phase III studies did not allow L-DOPA dose reductions during 
the last 12 weeks of the study, but this would not be an issue in clinical practice where L-DOPA dose 
reductions within the first days to first weeks after initiating treatment are recommended according 
to the clinical condition of the patient [55]. As demonstrated in the efficacy evaluations of ON time 
with and without troublesome dyskinesia, most dyskinesia was deemed non-troublesome by the 
patients. Of note, in the BIPARK I study, 47 (80%) of 59 treatment-emergent dyskinesia occurred in 
patients (in all groups) who were already experiencing dyskinesia at baseline [44]. Furthermore, 
when AEs are broken down by time frame, it becomes apparent that whereas the rates of dyskinesia 
AEs are higher for opicapone 50 mg vs entacapone 200 mg during the first 2 weeks of treatment 
(before Visit 4: 12.2% with opicapone versus 5.7% with entacapone), the rates of dyskinesia are 
actually very similar after this initial period (after Visit 4: 4.3% with opicapone versus 4.1% with 
entacapone) [38].  
 
Another safety aspect of special interest to COMT inhibitors is hepatic safety, which has been the 
most important limitation of tolcapone [25] and other COMT inhibitors in development. It is 
therefore of importance that, across both pivotal studies, there was no apparent increase in hepatic 
disorders with opicapone. Indeed, the overall incidence of drug-related hepatic disorders was lower 
with opicapone compared to placebo (1.2% vs. 3.1%), there were no relevant differences between 
groups in the mean changes from baseline to endpoint for hepatic laboratory parameters and no 
severe hepatic events were reported with opicapone in the pivotal trials [56].  
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Likewise, the utility of entacapone can be limited in some patients by the development of 
gastrointestinal problems such as severe diarrhea. In the BIPARK I study, the most common TEAEs 
leading to discontinuation was diarrhea, but these patients came from the entacapone (n=2) and 
placebo (n=1) groups, and no patient in the opicapone groups discontinued due to diarrhea [44]. 
Opicapone is not associated with urine discoloration [44] or orange staining of teeth, hair  or nails 
associated with entacapone administration [57]. Although not a serious medical problem, patients 
can find this staining embarrassing.  
 
A pooled analysis of data collected with the modified Minnesota Impulsive Disorders Interview 
(mMIDI) found that opicapone, like all current dopaminergic PD medications, is associated with an 
increase in impulse control disorders. In the BIPARK I study (which excluded patients with current 
impulse control disorders, and where baseline medication use was broadly similar across groups) the 
overall incidence of treatment-emergent impulse control disorders (as identified by the mMIDI) was 
highest in the entacapone group (8.2%), followed by opicapone (6.2%) and then placebo (4.1%). 
There was no dose relationship in the opicapone groups [44]. The most common disorders seen in 
both studies were buying disorders and changes in sexuality (hypersexuality, sexual excitability, 
compulsive sexual behavior) [44].  
 
Finally, it is important to note that most patients in this advanced group of PD patients are on 
multiple medications. Subgroup analyses to evaluate the effect of concurrent usage of MAO 
inhibitors and dopamine agonists for PD treatment, as identified at baseline, showed that opicapone 
presented similar efficacy when used alone or concomitantly [58]. Just as importantly, there were no 
differences in the incidence of TEAEs between opicapone patients treated with or without these 
adjunct agents, thereby supporting the role of opicapone in a polypharmacy approach.  
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3.6 Regulatory affairs  
On the 24th June 2016, Ongentys (opicapone) received a Marketing Authorization approval from the 
European Commission as adjunctive therapy to preparations of L-DOPA/DOPA decarboxylase 
inhibitors (DDCIs) in adult patients with PD and end-of-dose motor fluctuations who cannot be 
stabilized on those combinations [40]. The recommended dose is 50 mg, taken once a day at 
bedtime, at least one hour before or after L-DOPA combination medicines. 
 
Ongentys is approved as 25mg and 50mg hard capsules in packs of 10, 30 or 90 capsules [40]. As a 
new active substance, opicapone is authorized in the European Union member states under the 
Anatomical therapeutic chemical (ATC) code of N04 (Anti-parkinson drugs), with additional 
monitoring in place. Following an exclusive license agreement, the Japanese company - Ono 
Pharmaceutical Co., Ltd. will develop opicapone for use in Japan. No plans have yet been announced 
for filing with the US Food and Drug Administration. 
 
3.7 Conclusion  
Opicapone is a third generation, highly potent and effective COMT inhibitor that optimizes the 
pharmacokinetics of L-DOPA therapy, with the unique characteristic of once daily dosing. Across all 
clinical studies, opicapone consistently reduced OFF-time and increased ON-time without increasing 
the frequency of troublesome dyskinesia, and these benefits were maintained over at least a year of 
continued open-label therapy.  
 
The impact of reducing OFF time and increasing ON time in patients with PD and motor fluctuations 
is well established and the efficacy of opicapone is further supported by the significant benefits in 
terms of clinician rated and patient rated global function.  Although the BIPARK I study was not 
powered to compare opicapone with entacapone treatment, the results favored opicapone – 
indicating that opicapone may offer greater improvements in increasing ON time and decreasing 
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OFF time. Supporting these observations, patients receiving opicapone once-daily experienced 
statistically significant improvements in their functioning or well-being compared to entacapone 
(investigator rated P=0.007; patient rated p=0.0091).  
 
3.8 Expert commentary  
Long–term studies have shown that starting treatment with either a dopamine agonist or a selective 
MAO-B inhibitor confer little or no long-term advantage compared to L-DOPA [59-61].  Together 
with concerns about dopamine agonist-induced impulse control disorders these studies have 
supported a general swing away from dopamine agonist monotherapy back to early L-DOPA 
treatment [61].  Nevertheless, higher cumulative doses (>400–600mg) of L-DOPA are strongly 
correlated with the earlier emergence of motor complications [6, 62], and the presence of wearing-
off is associated with the earlier development of dyskinesia and vice versa [63]. Adjunct therapies to 
control motor fluctuations are high on the list of clinical need for patients on sustained L-DOPA 
treatment, and opicapone will take its place in the PD armamentarium as a novel and effective 
adjunctive option. Opicapone offers an important alternative to entacapone, with convenient once-
daily dosing and potential efficacy advantages. 
 
3.9 Five-year view 
Despite some exciting prospects of potentially disease-modifying activity of novel interventions that 
target the aggregation and propagation of toxic alpha-synuclein species, improved symptomatic 
therapies will likely dominate the PD drug market over the next five years. These will include 
innovations of L-DOPA formulation and delivery where a clinical development program of 
continuous subcutaneous infusions of L-DOPA/carbidopa has shown promising Phase II results in PD 
patients with L-DOPA related motor complications. This formulation has been reported to more 
reliably achieve L-DOPA plasma levels in the therapeutic range that are likely needed for patients 
with motor fluctuations when co-administered with entacapone [31], opening interesting 
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perspectives for the future use of once-daily COMT-inhibitors like opicapone. The efficacy of 
opicapone with the various extended release L-DOPA formulations coming to market (e.g. IPX066 
and the gastric-retention formulation) will need to be evaluated, in particular if a combination of 
opicapone with extended-release L-DOPA from the outset of treatment can reduce the incidence 
and severity of motor complications. Other reformulations include the development of an inhaled L-
DOPA and a novel sublingual apomorphine formulation, both of which are in Phase III clinical 
development. While these fast acting medications are unlikely to replace classical adjunct 
approaches, they would be expected to supplement oral regimens as rescue medication for 
intervening OFF-periods.  
 
In the next five years, the role of opicapone in clinical practice will become clearer with routine use.  
Only clinical experience with opicapone will show if the efficacy benefits versus entacapone 
suggested by the BIPARK-I study will translate into routine practice. Further pharmacogenetics 
research involving COMT polymorphisms may allow pre-treatment determination of patients likely 
to respond well to opicapone. 
 
Key issues 
 The effective management of motor fluctuations is key to the global health status and well-
being of patients with PD.  
 Opicapone is a third generation, potent and effective catechol O‑methyltransferase (COMT) 
inhibitor that provides long-lasting COMT inhibition to optimize the pharmacokinetics and 
bioavailability of L-DOPA therapy.  
 In PD patients with motor fluctuations, opicapone 50 mg given once-daily, consistently 
reduced OFF-time and increased ON-time without increasing the frequency of troublesome 
dyskinesia. 
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 The BIPARK I pivotal study included entacapone (200mg with each L-DOPA dose) as an active 
comparator. Patients receiving opicapone once-daily experienced greater improvements in 
their global health status (as assessed by both the Clinician´s and Patient’s Global Impression 
of Change) versus entacapone. 
 The efficacy of opicapone on reducing OFF time and increasing ON time are maintained over 
at least a year of continued open-label therapy. During a 1-year open-label follow-up period, 
patients switching from entacapone to opicapone once-daily achieved additional increases 
in ON-time.  
 Opicapone is generally well-tolerated. The most common treatment-related adverse events 
were dyskinesia, constipation, insomnia, dry mouth and dizziness. Treatment with 
opicapone has not been associated with the development of liver problems, diarrhea and 
urinary discoloration. 
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Table legends 
Table 1. Treatment-emergent adverse events in >3% of any treatment group, by 
decreasing frequency all completed Phase III double-blind studies (Safety Set) 
 
Figure legends 
Figure 1: Opicapone chemical structure 
 
Figure 2: Dose dependent COMT inhibition in (a) healthy volunteers and (b) PD patients with 
motor fluctuations [39, 43]  
[Legend]: Figure 2a shows Mean S-COMT activity on Day 12 following once daily oral administration 
of 50mg opicapone or placebo for 11 days (Day 1 to 11) or co-administration of 200mg entacapone 
or placebo with each L-dopa/carbidopa dose (n=15) 
 
Figure 3: Clinician´s Global Impression of Change (CGI-C) and the Patient’s Global Impression of 
Change (PGI-C) in the BIPARK-I study. Adapted from reference [44] 
Legend: Improved includes patients ‘minimally improved’, much improved’ and ‘very much 
improved’.  
 
Figure 4: Change from baseline in ON (upper part) and OFF (lower part) time (minutes) 
[Legend]: Pooled analysis from the BIPARK I and BIPARK II studies  
 
Figure 5: BIPARK-I study: OFF-time change from double-blind baseline to double-blind endpoint 
and open-label endpoint.  
[Legend]: All patients switched to active treatment with opicapone at the start of the open-label 
phase. *p<0.05 vs. pre-switch.  
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Figure 6: Change from double-blind baseline in (an) absolute OFF-time (b) absolute ON time 
without or with non-troublesome dyskinesia and (c) ON time with troublesome dyskinesia 
(BIPARK II study) 
 
 
